secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2021-09-09T23:59:59+00:00
Accession:  0000950170-21-001739
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio reports Q2 net loss $11.1M; IPO gross proceeds $92.7M; pipeline on track for Phase 1 starts in Q1 2022
--------------------------------------------------------------------------------

- Net loss of $11.1M ($2.80 per common unit) for Q2 2021, vs $4.9M in Q2 2020.
- Cash and investments $112.7M as of June 30; August IPO added ~$83.2M net proceeds.
- R&D expenses $6.8M in Q2 2021, up from $3.1M YoY, driven by RLYB212 and RLYB116 development.
- Phase 1/2 data for RLYB211 (FNAIT) presented at ISTH; additional data expected Q4 2021.
- Phase 1 studies of RLYB212 and RLYB116 planned to initiate in Q1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017021001739/0000950170-21-001739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017021001739/rlyb-20210909.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer